Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.

Annick MoensBram VerstocktDahham AlsoudJoão SabinoMarc Ferrante Severine Vermeire

Published in: Inflammatory bowel diseases (2021)

This real-world cohort study of biologic-naïve IBD patients found VDZ to be superior to ADM as first-line treatment for patients with UC-but not CD-regarding endoscopic remission at week 52 and treatment persistence.

Keyphrases

ulcerative colitis
end stage renal disease
rheumatoid arthritis
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
high intensity
early onset
ultrasound guided
disease activity
patient reported outcomes
systemic lupus erythematosus
juvenile idiopathic arthritis